Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering
05 mars 2024 08h00 HE
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., March 05, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today...
Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies
04 mars 2024 08h00 HE
|
Quoin Pharmaceuticals, Inc.
Clearance to include teen patients in both the company’s open label and placebo controlled studies expected to significantly expand the number of eligible subjects, potentially expedite recruitment...
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
28 févr. 2024 18h03 HE
|
Catalyst Pharmaceuticals, Inc.
Achieved Record 2023 Total Revenues of $398.2 Million, an 85.9% Increase Compared to 2022 Achieved Record Fourth Quarter 2023 Total Revenues of $110.6 Million, an 82.0% Increase Compared to...
Zealand Pharma Announces Financial Results for the Full Year 2023
27 févr. 2024 01h00 HE
|
Zealand Pharma
Company announcement - No. 9 / 2024 Zealand Pharma Announces Financial Results for the Full Year 2023 Significant progress delivered across our obesity and rare disease assets while building a...
Tricha Shivas Promoted to Chief of Staff and Strategy at Foundation for Sarcoidosis Research
15 févr. 2024 06h23 HE
|
Foundation for Sarcoidosis Research
The Foundation for Sarcoidosis Research (FSR) proudly announces the promotion of Tricha Shivas to Chief of Staff and Strategy.
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
14 févr. 2024 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
12 févr. 2024 16h06 HE
|
Biogen Inc.
Friedreich’s ataxia is a rare, genetic, life-shortening, debilitating, and neurodegenerative disorderTreatment with SKYCLARYS improved patient function compared to placeboBiogen is leveraging its...
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review
06 févr. 2024 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
- ATH434-201 Trial on Track to Complete in November 2024 – - Top-Line Data Expected in January 2025 - MELBOURNE, AUSTRALIA AND SAN FRANCISCO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Alterity...
Texas Infant to Become Fifth Child to Receive Life-Saving Gene Therapy Treatment on U.S. Soil
05 févr. 2024 11h14 HE
|
The Calliope Joy Foundation
DALLAS, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Sufyan Pashai, a 4-month-old from Dallas, will travel to Minnesota and become the fifth child to receive life-saving gene therapy treatment on U.S. soil for...
Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week
29 janv. 2024 07h24 HE
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...